Article Information
- Received May 15, 2006
- Revision received November 13, 2006
- Accepted November 16, 2006
- First published December 27, 2006.
- Version of record published December 27, 2006.
Author Information
- Michael J. Saganich1,*,
- Brock E. Schroeder2,*,
- Veronica Galvan3,
- Dale E. Bredesen3,
- Edward H. Koo2, and
- Stephen F. Heinemann1
- 1Salk Institute for Biological Studies, La Jolla, California 92037,
- 2Department of Neurosciences, University of California at San Diego, La Jolla, California 92037, and
- 3Buck Institute for Age Research, Novato, California 94945
- Correspondence should be addressed to Dr. Michael J. Saganich, Salk Institute for Biological Sciences, 10010 North Torrey Pines Road, La Jolla, CA 92037. saganich{at}salk.edu
Author contributions
-
↵*M.J.S. and B.E.S. contributed equally to this work.
Disclosures
- Received May 15, 2006.
- Revision received November 13, 2006.
- Accepted November 16, 2006.
-
This work was supported in part by National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke Grant 5 R01 NS2809 (S.F.H.), NIH/National Institute on Aging Grant P01 AG10435-12 (S.F.H.), NIH Grant AG05131 (D.E.B., E.H.K.), AG00216 (M.J.S., B.E.S), and NS45093 (D.E.B.), Fidelity Foundation (S.F.H.), Ellison Medical Foundation (S.F.H.), Alzheimer's Association Grants IRG04-1181 (E.H.K.) and NIRG-04-1054 (V.G.), and the Joseph Drown Foundation (D.E.B.). We thank Dr. Lennart Mucke for providing the PDAPP(J9) and PDAPP(J20) lines. The monoclonal antibody E7 developed by Michael Klymkowsky was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the National Institute of Child Health and Human Development and maintained by The University of Iowa, Department of Biological Sciences (Iowa City, IA).
- Correspondence should be addressed to Dr. Michael J. Saganich, Salk Institute for Biological Sciences, 10010 North Torrey Pines Road, La Jolla, CA 92037. saganich{at}salk.edu
Online Impact